Found: 7
Select item for more details and to access through your institution.
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma.
- Published in:
- European Journal of Immunology, 2024, v. 54, n. 2, p. 1, doi. 10.1002/eji.202350637
- By:
- Publication type:
- Article
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma.
- Published in:
- JAMA Surgery, 2024, v. 159, n. 8, p. 881, doi. 10.1001/jamasurg.2024.1184
- By:
- Publication type:
- Article
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 6, p. 1661, doi. 10.3390/cancers15061661
- By:
- Publication type:
- Article
How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2043, doi. 10.3390/cancers13092043
- By:
- Publication type:
- Article
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.
- Published in:
- Liver International, 2024, v. 44, n. 7, p. 1588, doi. 10.1111/liv.15855
- By:
- Publication type:
- Article
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 1, p. 29, doi. 10.1007/s11523-023-01029-6
- By:
- Publication type:
- Article
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib.
- Published in:
- Internal & Emergency Medicine, 2024, v. 19, n. 4, p. 1151, doi. 10.1007/s11739-024-03578-8
- By:
- Publication type:
- Article